Nilotinib (AMN-107)

Catalog No.S1033

Nilotinib (AMN-107) Chemical Structure

Molecular Weight(MW): 529.52

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
Features A selective inhibitor of native and mutant Bcr-Abl.
Targets
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
In vitro

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqwTWM2OD1yLkCwNFE1PCEQvF2= NGfxWopUSU6JRWK=
KU812 MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjmZpRKSzVyPUCuNFAzPDhizszN NUL3dohCW0GQR1XS
EM-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\STWM2OD1yLkCwOFEh|ryP MX7TRW5ITVJ?
LAMA-84 NGnC[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEC0PUDPxE1? MXTTRW5ITVJ?
MEG-01 NGHSUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\rUohKSzVyPUCuNFA5OjhizszN MmHTV2FPT0WU
BV-173 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjuXVZKSzVyPUCuNFExQDlizszN M37OcHNCVkeHUh?=
KASUMI-1 NWXNOmdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDLcpJ1UUN3ME2wMlAzPDF|IN88US=> NUXoeVYzW0GQR1XS
NB7 M4nUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrIdXlwUUN3ME2wMlE{PDN7IN88US=> NYnpcnVGW0GQR1XS
BHT-101 NVfNOGRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e2N2lEPTB;MD62OFI3OyEQvF2= MUDTRW5ITVJ?
CGTH-W-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwNkS4O{DPxE1? MWnTRW5ITVJ?
HMV-II MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTnVnFSUUN3ME2wMlc1QDd2IN88US=> NGm3WoNUSU6JRWK=
NKM-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwOUCxOUDPxE1? MXjTRW5ITVJ?
LB2241-RCC NXzIRZFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknHTWM2OD1zLkCyNlI5KM7:TR?= NXPIZlJoW0GQR1XS
NCI-H1703 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXNTWM2OD1zLkG4PFch|ryP NWXSOpFsW0GQR1XS
BE-13 NYjMTVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XPOGlEPTB;MT6yO|QyPiEQvF2= M3nUbnNCVkeHUh?=
ACN NIjWRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\uS|JKSzVyPUGuOVUxPzdizszN NGSycIlUSU6JRWK=
A204 NXvUUFJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz1ZVJxUUN3ME2xMlU4OjB3IN88US=> MnXYV2FPT0WU
HOP-62 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DZPWlEPTB;MT64NlA4PyEQvF2= M3LYR3NCVkeHUh?=
H9 NH[2fVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvh[GtRUUN3ME2yMlc{Pzl|IN88US=> NYezVndkW0GQR1XS
HCC1806 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwN{SzNlch|ryP MXHTRW5ITVJ?
NOS-1 NH75WG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjtdGxKSzVyPUKuPFcyODJizszN MUTTRW5ITVJ?
RS4-11 M4nwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G4OGlEPTB;Mj65NFYzOyEQvF2= NYfGR3pSW0GQR1XS
JAR MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D5c2lEPTB;Mj65NlA5PCEQvF2= M2\PVXNCVkeHUh?=
T98G Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPtdFVVUUN3ME2zMlAyOzF|IN88US=> NFzDWGpUSU6JRWK=
NCI-SNU-1 M{TsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXLXmdKSzVyPUOuOFAxQTJizszN MYPTRW5ITVJ?
SK-MEL-1 M3;YUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn6TWM2OD1|LkSzNFI6KM7:TR?= M3j4UnNCVkeHUh?=
L-363 NH6zN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTmfXA2UUN3ME2zMlYyOTB5IN88US=> MmPYV2FPT0WU
SW982 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXoe4RxUUN3ME2zMlY1OTZ7IN88US=> NYTLO5BzW0GQR1XS
HT-1080 NUXISHhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXvNW1KSzVyPUOuPVE4PzVizszN NUHjNmNDW0GQR1XS
G-402 MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLKWGhlUUN3ME20MlMyOjB|IN88US=> MY\TRW5ITVJ?
HOS NYS3[pJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi4WHVKSzVyPUSuPFAzQDJizszN NVPCV|lsW0GQR1XS
SK-NEP-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGOwbGhKSzVyPUSuPFMyQTFizszN NUm1b3B5W0GQR1XS
HAL-01 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzVUnhKSzVyPUSuPFgzPDJizszN NUjCc25qW0GQR1XS
SBC-1 NULZSXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jVWGlEPTB;ND65NFkxPyEQvF2= M2PrU3NCVkeHUh?=
CTV-1 M{C3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTVwNEi5N|gh|ryP MVjTRW5ITVJ?
LCLC-103H MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrsXYtKSzVyPUWuO|c1PzFizszN M{nnbHNCVkeHUh?=
RVH-421 NHznb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LMdmlEPTB;NT63O|U{PiEQvF2= M1\6NnNCVkeHUh?=
K-562 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nUUmlEPTB;NT65NFM3KM7:TR?= MVHTRW5ITVJ?
CAL-33 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXnXFJKSzVyPU[uN|E{PTlizszN MYjTRW5ITVJ?
MDA-MB-361 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nkV2lEPTB;Nj6zN|Y6QSEQvF2= M2TuSXNCVkeHUh?=
IGROV-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L5[WlEPTB;Nj60O|E6OSEQvF2= MWPTRW5ITVJ?
NY M1jwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TrVWlEPTB;Nj61N|U6QSEQvF2= MULTRW5ITVJ?
Ramos-2G6-4C10 M2ja[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuxUG5KSzVyPU[uOlY6OzFizszN MUnTRW5ITVJ?
HuO9 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXsTWM2OD14LkezPVY1KM7:TR?= M17PbHNCVkeHUh?=
MS-1 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PKTGlEPTB;Nz6xNVk2OyEQvF2= M2f5bXNCVkeHUh?=
RPMI-8226 NULZb406T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTdwMkiyPFch|ryP NHnFenZUSU6JRWK=
HDLM-2 NIDjb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTdwNECxOFkh|ryP NIL3dIpUSU6JRWK=
D-566MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTdwNEexOVUh|ryP MlX6V2FPT0WU
SK-MEL-24 NVLpSY1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfZXVRKSzVyPUeuOlM{QTJizszN NUDSOWZtW0GQR1XS
COLO-679 M1n0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTdwOUi2O|Eh|ryP MnjSV2FPT0WU
EW-13 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;l[WhKSzVyPUiuN|IxPTRizszN MWXTRW5ITVJ?
A388 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;4TWM2OD16LkO4OFgyKM7:TR?= MUPTRW5ITVJ?
UM-UC-3 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW3b4VKSzVyPUiuOFM6PTZizszN M3rle3NCVkeHUh?=
NUGC-3 NGrR[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LFO2lEPTB;OD61N|U5OiEQvF2= MYXTRW5ITVJ?
COLO-668 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfRTWM2OD16LkW5OFkyKM7:TR?= Mn3LV2FPT0WU
MOLT-4 NWrNOHdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTsTWM2OD16Lk[yN|U{KM7:TR?= M2XDT3NCVkeHUh?=
D-423MG NF7G[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrtNppKSzVyPUiuPFM4PTZizszN MmC3V2FPT0WU
CTB-1 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPJTGxKSzVyPUiuPFcyOjhizszN MnW1V2FPT0WU
BCPAP NG\tTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vYNWlEPTB;OT6wNlU3OiEQvF2= NUjje4k1W0GQR1XS
GCT NF\CfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTlwMEm4N|Eh|ryP M3LzeHNCVkeHUh?=
ACHN NVrjUXFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjnfW9KSzVyPUmuNlM3OzJizszN MmWwV2FPT0WU
KYSE-520 M{TVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTlwM{O0PFIh|ryP NYTDfJdiW0GQR1XS
LB771-HNC M4exS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLT[|VKSzVyPUmuO|Y1QTdizszN MkSwV2FPT0WU
MLMA MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Zbo5KSzVyPUGwMlAyOzJizszN MWPTRW5ITVJ?
HEC-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3PTWM2OD1zMD6yPFA1KM7:TR?= NFXROZhUSU6JRWK=
HL-60 NED5VWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13lbmlEPTB;MUCuOlg2OyEQvF2= M{X3RXNCVkeHUh?=
A101D NWLyRW9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFyLki5NlMh|ryP NFv0WYFUSU6JRWK=
A2058 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\pbYNKSzVyPUGwMlkzPDVizszN Ml:0V2FPT0WU
KARPAS-45 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETzOXBKSzVyPUGxMlA3OzVizszN NWW2eWdSW0GQR1XS
697 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFzLkKxNFEh|ryP NH:3[XRUSU6JRWK=
NCI-N87 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\KO2xKSzVyPUGxMlc4OzFizszN NEDENHpUSU6JRWK=
DSH1 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDFTWM2OD1zMT63PVU{KM7:TR?= M1HqOXNCVkeHUh?=
HLE NGXPVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFzLki4N|kh|ryP M3L6XXNCVkeHUh?=
NCI-H720 NGjuWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPNTWM2OD1zMj62PFAyKM7:TR?= NU\vOmtzW0GQR1XS
EW-3 M2HJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF{LkmzNFch|ryP M1LXT3NCVkeHUh?=
AGS M{jZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDGTWM2OD1zMz6wN|UyKM7:TR?= NImzfGVUSU6JRWK=
ES5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTqbJZJUUN3ME2xN{4xPTF{IN88US=> NUTCNnE6W0GQR1XS
DB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fvfWlEPTB;MUOuN|I2PiEQvF2= MUDTRW5ITVJ?
A4-Fuk Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH4UlZKSzVyPUGzMlQyODJizszN NGHrSohUSU6JRWK=
A427 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnTN25KSzVyPUGzMlQ6PzJizszN MkXZV2FPT0WU
MN-60 NVfpW5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDMN5RKSzVyPUGzMlU5PDNizszN M3LtNnNCVkeHUh?=
HCC2218 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULWUGFRUUN3ME2xN{42QDV4IN88US=> M2fpdHNCVkeHUh?=
MV-4-11 NUS3[2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TPTmlEPTB;MUOuPFE{PyEQvF2= MoDvV2FPT0WU
GI-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF2LkGxPFQh|ryP MWTTRW5ITVJ?
JVM-3 NXrwUHVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i2WmlEPTB;MUSuNlY2PiEQvF2= MWPTRW5ITVJ?
NCI-H2029 NFPVR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITx[21KSzVyPUG0MlI4OjdizszN NFmzcm1USU6JRWK=
TE-12 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXtTWM2OD1zND62NFQ3KM7:TR?= MWjTRW5ITVJ?
WM-115 M2f4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:yN2lEPTB;MUWuOVY5OyEQvF2= NXrGOXpbW0GQR1XS
BB65-RCC NVPxNGlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXWTWM2OD1zNj6wNlQyKM7:TR?= MUDTRW5ITVJ?
NCI-H1693 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS3TWM2OD1zNj6zPFAzKM7:TR?= NFnUdJZUSU6JRWK=
KARPAS-299 NGTzRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXyfpRKSzVyPUG2MlYzODNizszN NFS5UlNUSU6JRWK=
UACC-257 NIDP[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXmRnFTUUN3ME2xO{4xPTh{IN88US=> MVvTRW5ITVJ?
RKO M2H0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rVXmlEPTB;MUeuOlQ{OyEQvF2= NUSy[4pvW0GQR1XS
HT-29 NGXMZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3RTWM2OD1zNz63PFg6KM7:TR?= M{D0S3NCVkeHUh?=
ES7 NV\LeYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfr[3lKSzVyPUG4MlEyOjJizszN M4TYNHNCVkeHUh?=
DEL NGCwT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF6LkOxO|Ih|ryP NYTHWGIyW0GQR1XS
BT-549 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF6LkSwPVIh|ryP MWfTRW5ITVJ?
NCI-H1755 NVzhS5QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVntWYRvUUN3ME2xPE42PzJ|IN88US=> MYTTRW5ITVJ?
HCE-T MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLlTWM2OD1zOD64N|QyKM7:TR?= M3ewSXNCVkeHUh?=
LU-139 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTNTWM2OD1zOT6wOFU5KM7:TR?= M2HHV3NCVkeHUh?=
ECC10 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fWNGlEPTB;MUmuNlQ4PSEQvF2= M{fHWXNCVkeHUh?=
769-P M2nxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7QeWI{UUN3ME2xPU43OzN3IN88US=> NE\rVnVUSU6JRWK=
BALL-1 M13CbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnZPYZ1UUN3ME2xPU43Pzd3IN88US=> NHHpTVVUSU6JRWK=
LXF-289 M1vEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF7Lki5O|kh|ryP NUX4ZnIxW0GQR1XS
TYK-nu NUewS3JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M322cmlEPTB;MUmuPVMyPSEQvF2= NUfNWYloW0GQR1XS
NCI-H630 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF7LkmzO|gh|ryP NYCydZdrW0GQR1XS
EW-18 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHZTWM2OD1{MD6zPFAzKM7:TR?= M2\wXXNCVkeHUh?=
KYSE-150 NIjwPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn5bJdKSzVyPUKwMlcxPDdizszN NUD4ZWNvW0GQR1XS
LOXIMVI NHnENlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm0TWM2OD1{MD63OVg3KM7:TR?= NYrRXI5GW0GQR1XS
HuP-T3 M4j3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVztcXQ{UUN3ME2yNU4xQDV{IN88US=> NVK2elhHW0GQR1XS
MFE-280 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrSTWM2OD1{MT61Olc6KM7:TR?= MlPvV2FPT0WU
SK-OV-3 M2nq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrHUopKSzVyPUKxMlg1ODhizszN M{DyWHNCVkeHUh?=
QIMR-WIL MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLFTWM2OD1{Mj6wOFc5KM7:TR?= MlXZV2FPT0WU
NCI-H69 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzuPYFKSzVyPUKyMlQzQTlizszN NIWyd4tUSU6JRWK=
TE-5 MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn64TWM2OD1{Mj60PVY2KM7:TR?= NH7kfIdUSU6JRWK=
NCI-H1993 NX[xWWJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ{LkS5O|Eh|ryP NX75XIMxW0GQR1XS
NCI-H1092 M3rWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HqbmlEPTB;MkOuNlg1OyEQvF2= MV\TRW5ITVJ?
RH-1 NYS5eYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3ld3RZUUN3ME2yN{42OzV5IN88US=> MWnTRW5ITVJ?
DBTRG-05MG NVywS49kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[4TWM2OD1{Mz64OFczKM7:TR?= MW\TRW5ITVJ?
Mo-T M2fm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDWUY1[UUN3ME2yN{46KM7:TR?= M3nzNXNCVkeHUh?=
HD-MY-Z NWnvSFJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fqRWlEPTB;MkSuNlM3OiEQvF2= MY\TRW5ITVJ?
NCI-H2342 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ2Lk[3Olch|ryP NXT5OWxtW0GQR1XS
C32 NEKwSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LmUmlEPTB;MkSuPVU4PiEQvF2= NVLVco1bW0GQR1XS
HTC-C3 NXjlOHc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ3LkO1O|ch|ryP MlT2V2FPT0WU
NCI-H358 NV34Ulg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rVOGlEPTB;MkWuN|k1OyEQvF2= NF3NXmlUSU6JRWK=
CAL-85-1 M3LwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13obmlEPTB;MkWuOFU4PyEQvF2= NED6fFhUSU6JRWK=
HT-1197 M{DoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWWyXHVbUUN3ME2yOU42OzF7IN88US=> NHLuNY5USU6JRWK=
A172 M1X2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf6UWFKSzVyPUK1MlcyOzZizszN M2LIOXNCVkeHUh?=
SW1573 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHvUnJKSzVyPUK1Mlc4QDVizszN MX;TRW5ITVJ?
EW-24 NGrU[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOyT2hvUUN3ME2yOU46PjJizszN M3HhTnNCVkeHUh?=
SK-MEL-2 MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELZTINKSzVyPUK2MlA{OTJizszN Mlj6V2FPT0WU
LU-65 NEXmXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf5TWM2OD1{Nj6wOFUzKM7:TR?= NEnwO3ZUSU6JRWK=
KMOE-2 M{Wzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\CTWM2OD1{Nj6wPVE2KM7:TR?= M{m2OnNCVkeHUh?=
H-EMC-SS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq3[nFKSzVyPUK2MlQyOTRizszN MX7TRW5ITVJ?
H4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK2Z|ZQUUN3ME2yOk41OjR|IN88US=> M2TtTnNCVkeHUh?=
DU-4475 NF3BZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\PTWM2OD1{Nz6xPFczKM7:TR?= M2LuWHNCVkeHUh?=
HCT-116 MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TXNWlEPTB;MkeuOFM1QSEQvF2= NUDYNZJTW0GQR1XS
MSTO-211H NX7xd2V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPWTWM2OD1{Nz62NlU2KM7:TR?= M1zoVXNCVkeHUh?=
NCI-H292 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrzN2RwUUN3ME2yO{46PjF5IN88US=> NEHlOJBUSU6JRWK=
NCI-H446 Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnkZmlyUUN3ME2yPE4zOTB3IN88US=> MVjTRW5ITVJ?
NCI-H2009 M3jyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHezOFNKSzVyPUK5MlE1OzFizszN MkK2V2FPT0WU
MHH-ES-1 NUnO[oZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXYTWM2OD1{OT6zOlg2KM7:TR?= NXvwZXNbW0GQR1XS
TI-73 NI\B[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\FTWM2OD1{OT60NFAyKM7:TR?= MYfTRW5ITVJ?
NCI-H2228 M3;4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ7LkS1PEDPxE1? NV;IWZNIW0GQR1XS
MHH-PREB-1 NEfJelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fpfWlEPTB;MkmuOVUxPSEQvF2= NY\MbmZiW0GQR1XS
ChaGo-K-1 M3;VeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe2UIN7UUN3ME2yPU43ODl5IN88US=> NIXSelZUSU6JRWK=
KY821 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrHPYV3UUN3ME2yPU43PDN|IN88US=> MXvTRW5ITVJ?
NCI-H209 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLkdXFQUUN3ME2yPU45OzZ4IN88US=> NFTNT2hUSU6JRWK=
NBsusSR M4P2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\kSIFpUUN3ME2yPU46QTB2IN88US=> MmS5V2FPT0WU
NCI-H1304 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTndJBGUUN3ME2zNE42PzF4IN88US=> NGLoN|dUSU6JRWK=
NB14 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNzLkC0OFYh|ryP MWPTRW5ITVJ?
HCC1419 M2nkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrUW4pxUUN3ME2zNU4zPCEQvF2= M4TJPHNCVkeHUh?=
KG-1 NVnKWZNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\r[VVKSzVyPUOxMlc1OjlizszN NVvS[|NUW0GQR1XS
A2780 M1Pwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfwe3RsUUN3ME2zNU45OzV6IN88US=> MoXtV2FPT0WU
NCI-H28 M33vWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXCVYdKSzVyPUOxMlk5PjFizszN Mn\0V2FPT0WU
C2BBe1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33rTmlEPTB;M{KuNlY{PCEQvF2= MWfTRW5ITVJ?
VA-ES-BJ NH3HT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LwUWlEPTB;M{KuN|Eh|ryP MoflV2FPT0WU
SBC-5 NYTIPHpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7WTWM2OD1|Mj64OVEyKM7:TR?= NHfiV|JUSU6JRWK=
OVCAR-4 NWjCO3VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnId29KSzVyPUOzMlQ5PDhizszN MXLTRW5ITVJ?
COR-L88 M2XnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS5bZFtUUN3ME2zOE4xPzRzIN88US=> MknRV2FPT0WU
SW954 NInKNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\PTWM2OD1|ND6wO|UzKM7:TR?= MVXTRW5ITVJ?
COLO-684 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XD[mlEPTB;M{SuN|QxPCEQvF2= MXnTRW5ITVJ?
HCC70 NV\kPGhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTN2Lkm1NVQh|ryP Mo\PV2FPT0WU
NCI-H1770 M1TLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILtOpRKSzVyPUO0Mlk3OSEQvF2= MW\TRW5ITVJ?
NCI-H1666 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnpSHpKSzVyPUO1MlgzPTNizszN NXfRU21KW0GQR1XS
YH-13 M4THNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN3LkmyJO69VQ>? MYDTRW5ITVJ?
DJM-1 NGTMeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PUSWlEPTB;M{[uPFA1QSEQvF2= NUiwc3JDW0GQR1XS
KNS-62 NFnwUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHtTWM2OD1|Nj65OFM5KM7:TR?= M1vqVHNCVkeHUh?=
SK-MEL-30 M1Lse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGwfnJKSzVyPUO3Mlg4OzdizszN NGPaNWJUSU6JRWK=
SJRH30 NFLLdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PRcWlEPTB;M{iuO|M1OSEQvF2= MWTTRW5ITVJ?
GP5d MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDiZ2VIUUN3ME2zPE45PjV|IN88US=> NFuxRmxUSU6JRWK=
SW1116 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\wTWM2OD1|OT6yPFA2KM7:TR?= MkPEV2FPT0WU
COLO-800 NFn0ZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnVOphKSzVyPUO5MlM3OzhizszN M3LLZ3NCVkeHUh?=
RD MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXJWJVKSzVyPUO5MlUzPThizszN NFrWc2FUSU6JRWK=
NCI-SNU-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TLbWlEPTB;M{muOlkyPiEQvF2= M3TDOHNCVkeHUh?=
HuO-3N1 Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPZSWZKSzVyPUSwMlExQCEQvF2= Mn\SV2FPT0WU
SK-UT-1 M3PIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnVU5dKSzVyPUSwMlU3PzRizszN NEXMXY5USU6JRWK=
SK-MEL-3 NGH6O2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWzUVFJUUN3ME20NE42QTN{IN88US=> M3rKWXNCVkeHUh?=
SK-MEL-28 NGnWV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRyLk[0N|Uh|ryP NEf3T|lUSU6JRWK=
SCC-4 NETCeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTRzLkKxN|ch|ryP MV\TRW5ITVJ?
no-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRzLkezOVQh|ryP M{fVPHNCVkeHUh?=
HT-144 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTR{LkC1Olch|ryP MXPTRW5ITVJ?
MFM-223 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL6TWM2OD12Mj60NFIh|ryP NGGwfZlUSU6JRWK=
ONS-76 M1f2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq3cldKSzVyPUSyMlgxOThizszN NFi2[ZVUSU6JRWK=
ES8 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[xOoxKSzVyPUSzMlM3QThizszN M2joSnNCVkeHUh?=
T-24 NWLQNoJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jHfmlEPTB;NEOuOFM3QSEQvF2= NHLsSpRUSU6JRWK=
GAMG Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn6VHdKSzVyPUSzMlQ2OTdizszN M4njSnNCVkeHUh?=
LU-135 M{eweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXacGNIUUN3ME20OE4xQTJ|IN88US=> MW\TRW5ITVJ?
HCC1187 M2T4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPqTWM2OD12ND64NlYzKM7:TR?= NYHpR4o6W0GQR1XS
TE-1 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnpWJdSUUN3ME20OU4yPjV2IN88US=> MX3TRW5ITVJ?
J-RT3-T3-5 NGPOepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTR3LkSzNVUh|ryP MmG2V2FPT0WU
GI-ME-N MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDITWM2OD12NT64PVUzKM7:TR?= NVL5bpQ5W0GQR1XS
D-392MG MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjB[49CUUN3ME20OU46OjV4IN88US=> NFXHbFNUSU6JRWK=
KALS-1 M{S3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\IeGNGUUN3ME20Ok44OjV5IN88US=> NUPtUI9SW0GQR1XS
MMAC-SF Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPhd4VYUUN3ME20Ok46QTV{IN88US=> NWjPVohJW0GQR1XS
HSC-3 NEDrSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvUTWM2OD12Nz6zOlA5KM7:TR?= MWXTRW5ITVJ?
KM-H2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTR5Lk[wNFch|ryP MXHTRW5ITVJ?
LoVo MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjNPGs6UUN3ME20PE4yODB{IN88US=> NETJOpFUSU6JRWK=
NCI-H510A NHrkXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\td2lEPTB;NEiuNVg4OSEQvF2= M1\jcHNCVkeHUh?=
EW-11 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7MPHJkUUN3ME20PE4zOzR6IN88US=> MkLVV2FPT0WU
HCC2998 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPrTWM2OD12OD62NlM3KM7:TR?= MYTTRW5ITVJ?
J82 NVzjdI5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fRU2lEPTB;NEiuO|I1OiEQvF2= NVn2e3hoW0GQR1XS
ML-2 NFnQO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTR7LkS2NFUh|ryP M4S0N3NCVkeHUh?=
NCI-H2030 NEDneJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjkZ|E{UUN3ME20PU44OTF5IN88US=> MXrTRW5ITVJ?
NCI-H1792 NHvu[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojZTWM2OD12OT64OVE5KM7:TR?= MUDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AMPKα / AMPKα / p-AMPKβ1 / AMPKγ2 / p-LKB1 / LKB1 / CaMKIIβ ; 

PubMed: 23677989     


Dose-dependent analysis of AMPK-related molecules in HCC cells. Cells were exposed to nilotinib at the indicated concentrations for 24 h.

DNMT1 / DNMT3a / DNMT3b ; 

PubMed: 28720666     


Kasumi-1 or MV4-11 cells were treated for 24 h with the indicated doses of nilotinib and subjected western blot analysis to detect the expression levels of DNMT1, DNMT3a, DNMT3b.

pABL1 / p-NF-κB1 / NF-κB / STAT3 / p-STAT3 / IL-1β / IL-6 / COX2 ; 

PubMed: 31396300     


ABL1 regulated the inflammation signaling pathway. Blocking activities of ABL1 with Imatinib and Nilotinib inhibits the inflammatory signaling pathway including activities of NF-κB1, STAT3, IL-1β, IL-6, and COX2.

23677989 28720666 31396300
Growth inhibition assay
Cell viability; 

PubMed: 23677989     


Dose-dependent effects of nilotinib on cell viability. HCC cells were treated with nilotinib at the indicated concentrations for 72 h. Cell viability was measured by MTT assay. Points, mean; bars, S.D. (n = 8). 

23677989
In vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: Human primary Schwann and schwannoma cells
  • Concentrations: 1-10 μM
  • Incubation Time: 72 hours
  • Method: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • Formulation: 10% NMP-90% PEG300, PEG300
  • Dosages: 75 mg/kg, 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 529.52
Formula

C28H22F3N7O

CAS No. 641571-10-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04002674 Recruiting Drug: Placebo oral capsule|Drug: Nilotinib Oral Capsule Dementia With Lewy Bodies Georgetown University|National Institutes of Health (NIH) November 2019 Phase 2
NCT03942094 Not yet recruiting Drug: Nilotinib Chronic Myeloid Leukemia Chronic Phase|Nilotinib Shenzhen Second People''s Hospital June 1 2019 Phase 3
NCT03874858 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis March 22 2019 Phase 2
NCT02973711 Suspended Drug: Nilotinib|Drug: Ruxolitinib Leukemia Chronic Myeloid University of Michigan Rogel Cancer Center January 18 2018 Phase 1|Phase 2
NCT03228303 Not yet recruiting Drug: Nilotinib 150 MG [Tasigna]|Drug: Imatinib 400mg Chronic Myeloid Leukemia Assiut University December 1 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • Answer:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Tags: buy Nilotinib (AMN-107) | Nilotinib (AMN-107) supplier | purchase Nilotinib (AMN-107) | Nilotinib (AMN-107) cost | Nilotinib (AMN-107) manufacturer | order Nilotinib (AMN-107) | Nilotinib (AMN-107) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID